Evidence map›Paper›PMID 33551974›Full record

ArticleFrontiers in neurology2020

Duration of Treatment Effect Using IncobotulinumtoxinA for Upper-limb Spasticity: A

Petr Kaňovský, Elie P Elovic, Angelika Hanschmann, Irena Pulte, Michael Althaus, Reinhard Hiersemenzel, Christina Marciniak

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00432666 (Prospective, Double-blind, Placebo-controlled, Randomized, Multi-center Trial With an Open-label Extension Period to Investigate the Efficacy and Safety of incobotulinumtoxinA), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00432666 phase3completednot on this map

Prospective, Double-blind, Placebo-controlled, Randomized, Multi-center Trial With an Open-label Extension Period to Investigate the Efficacy and Safety of incobotulinumtoxinA (Xeomin) in the Treatment of Post-stroke Spasticity of the Upper Limb

TypeinterventionalSponsorMerz Pharmaceuticals GmbHRan2006 to 2008Enrolled148ConditionsPost-stroke Upper Limb SpasticityArmsIncobotulinumtoxinA (Xeomin), Placebo
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 3 countries.

Petr KaňovskýFaculty of Medicine and Dentistry and University Hospital, Palacký University Olomouc, Olomouc, Czechia.
Elie P ElovicMoss Rehabilitation, Philadelphia, PA, United States.
Angelika HanschmannMerz Pharmaceuticals GmbH, Frankfurt am Main, Germany.
Irena PulteMerz Pharmaceuticals GmbH, Frankfurt am Main, Germany.
Michael AlthausMerz Pharmaceuticals GmbH, Frankfurt am Main, Germany.
Reinhard HiersemenzelMerz Pharmaceuticals GmbH, Frankfurt am Main, Germany.
Christina MarciniakDepartment of Physical Medicine and Rehabilitation and the Department of Neurology, Northwestern University Feinberg School of Medicine and Shirley Ryan AbilityLab, Chicago, IL, United States.
MerLion Pharma (Germany) · DEMoss Rehabilitation Hospital · USNorthwestern University · USUniversity Hospital Olomouc · CZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The efficacy and safety of incobotulinumtoxinA ≤400 U was demonstrated in subjects with post-stroke upper-limb spasticity in a randomized, double-blind Phase 3 study with an open-label extension (OLEX; EudraCT number 2005-003951-11, NCT00432666). We report a

Indexed as

duration of effectincobotulinumtoxinApost-stroketreatment intervalupper-limb spasticity

Identifiers

PMID33551974
PMCPMC7862578
OpenAlexW3123487882

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.